The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Hitches Frequency’s Regenerative Hearing Loss Therapy Outside US
July 18, 2019
-
ORGANIZATION Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
-
BUSINESS Takeda Gears Up for Clinical Testing of 1st iPS-Derived CAR-T, Eyes Trial Launch in 2021
July 17, 2019
-
TRENDS Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
-
BUSINESS Simone Thomsen Tapped as Lilly Japan Chief; Patrik Jonsson to Take Big Job at HQ
July 12, 2019
-
ACADEMIA Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
-
ACADEMIA NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
-
BUSINESS Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
-
BUSINESS Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
July 9, 2019
-
BUSINESS Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
July 8, 2019
-
COMMENTARY Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
July 5, 2019
-
TRENDS Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
-
TRENDS Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
-
BUSINESS CheckMate-227 Lung Cancer Data Will Make or Break Opdivo’s Fate: Analyst
July 2, 2019
-
BUSINESS Takeda’s Medical Unit Revving Up “Patient First Program” as It Looks beyond the Pill
July 1, 2019
-
BUSINESS Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
June 28, 2019
-
REGULATORY Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
-
REGULATORY Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
June 26, 2019
-
COMMENTARY Filing for Sakigake Radiation Therapy Expected This Year for Head and Neck Cancer; Expanded Use, Overseas Development Eyed
June 25, 2019
-
BUSINESS ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…